STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions ...

For example, the claimed purity of IL2 is ≥95%. HPLC analysis of IL2 (a commercial product) and IL13 received from Professor Kakiuchi showed some impurities in IL2 but practically no impurities in ...

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The Dupixent development ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthma Itepekimab expanding into chronic ...

Itepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026 Paris, April 15, 2025. Sanofi today shared new ...

Also helping boost Regeneron’s business is the recent approval of its Sanofi-partnered Dupixent in COPD, making the IL4 and IL13 blocker the first-ever biologic cleared for this indication.

Dupixent sales are recorded by Sanofi, which co-develops the anti-IL4 and anti-IL13 antibody with Regeneron. Overall, Regeneron made $3.79 billion in the fourth quarter, a modest 1% beat versus the $3 ...

The study concluded that dupilumab may unmask or progress CTCL through IL13 receptor blockade, like its effect in atopic dermatitis. However, further evaluation is needed due to the limitations of the ...

Developed using Regeneron’s VelocImmune technology, Dupixent is a fully human monoclonal antibody that blocks the interleukin-4 (IL4) and interleukin-13 (IL13) signalling pathways. Regeneron and ...

Dupixent inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and the program focuses on a specific population of people with evidence of type 2 inflammation.